SBIR-STTR Award

Low Cost Screening Tool For Hollow Fiber Bioreactor Rand
Award last edited on: 4/25/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Michael J Gramer

Company Information

BioVest International Inc (AKA: Endotronics Inc~Cellex Biosciences Inc)

8500 Evergreen Boulevard Nw
Minneapolis, MN 55433
   (763) 786-0302
   investor@biovest.com
   www.biovest.com
Location: Multiple
Congr. District: 03
County: Anoka

Phase I

Contract Number: 1R43CA076829-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1998
Phase I Amount
$100,000
Hollow-fiber bioreactor technology is an economical alternative to traditional cell culture methods for the production of cells and cell- derived products, and is finding increased use for novel applications in the fields of tissue engineering, gene therapy, and pharmacology. Hollow-fiber bioreactors are also reducing the suffering of animals by serving as logical replacements for ascites production methods. However, a major drawback of hollow-fiber technology is an inherent lack of predictability; there is no efficient screening method to determine how well a new cell line will perform in a hollow-fiber system, or how well an established cell line will perform under new conditions. To address this problem, a small, inexpensive, and easy to use screening tool has been developed at CELLEX BIOSCIENCES. This tool incorporates the same fibers as in a production system, but requires no pumping for oxygenation or medium delivery so that dozens of conditions can be tested simultaneously in a single incubator. This research will be used to test the validity of this micro hollow-fiber screening tool as a predictor of cell line performance in large scale hollow fiber systems. This tool has the potential of substantially increasing the efficiency and reliability of hollow-fiber systems, much as screening tools such as 96-well plates have done for stirred tank systems. PROPOSED COMMERCIAL APPLICATION Most importantly, a low cost screening tool will be developed and validated to fill a current market need. CELLEX could also use this tool along with other information learned in this research to provide a battery of screening tests as an optimization service. In addition, a new medium formulation specifically optimized for hollow-fiber bioreactors could be developed in this research

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----